Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-58 |
Sentence |
denotes |
Antibody responses against SARS‐CoV‐2 in COVID‐19 patients |
T2 |
59-69 |
Sentence |
denotes |
LIU et al. |
T3 |
71-79 |
Sentence |
denotes |
Abstract |
T4 |
80-88 |
Sentence |
denotes |
Abstract |
T5 |
89-324 |
Sentence |
denotes |
The emerging coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a global pandemic, and brings formidable challenges to public health, society and the economy worldwide. |
T6 |
325-402 |
Sentence |
denotes |
Currently, the antibody responses against SARS‐CoV‐2 remains largely unknown. |
T7 |
403-570 |
Sentence |
denotes |
We herein estimated the longevity of specific antibodies against SARS‐CoV‐2, and reported that antibodies waned over substantially in COVID‐19 patients after recovery. |
T8 |
571-610 |
Sentence |
denotes |
This article is protected by copyright. |
T9 |
611-631 |
Sentence |
denotes |
All rights reserved. |